Agenovir Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Agenovir General Information

Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agenovir Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-May-2018 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 17-May-2016 000.00 000.00 000.00 Completed Generating Revenue
2. Grant 01-Jan-2016 $149K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Agenovir’s complete valuation and funding history, request access »

Agenovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Agenovir’s complete cap table history, request access »

Agenovir Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral re
Biotechnology
South San Francisco, CA
000.00
000000&0 000.00

000000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
0000000000000
Cambridge, MA
0 As of 0000
0000 0000-00-00
0000000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agenovir Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000000 Venture Capital-Backed Cambridge, MA 0 0000000000 0
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 0000 000000000 0000
000000000 Venture Capital-Backed New York, NY 00 0000 0000000000 0 0000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
You’re viewing 5 of 31 competitors. Get the full list »

Agenovir Patents

Agenovir Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3601568-A1 Antiviral therapeutic Inactive 31-Mar-2017 00000000000
US-20170246261-A1 Antiviral treatment with low immunogenicity Inactive 25-Feb-2016 0000000000
US-20170246260-A1 Modified antiviral nuclease Inactive 25-Feb-2016 0000000000
US-20170247690-A1 Oncoviral treatment with nuclease and chemotherapeutic Inactive 25-Feb-2016 000000000
US-20170247703-A1 Antiviral nuclease methods Inactive 25-Feb-2016 C12N15/1131
To view Agenovir’s complete patent history, request access »

Agenovir Executive Team (5)

Name Title Board Seat Contact Info
Dirk Thye MD Chief Executive Officer, President and Board Member
Stephen Quake Ph.D Co-Founder, Board Member & Chairman of the Scientific Advisory Board
Bolyn Hubby Ph.D Chief Scientific Officer
Angela Wu Co-Founder & Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

Agenovir Board Members (4)

Name Representing Role Since
Stephen Quake Ph.D Agenovir Co-Founder, Board Member & Chairman of the Scientific Advisory Board 000 0000
William Smith Agenovir Board Member, Intellectual Property 000 0000
You’re viewing 2 of 4 board members. Get the full list »

Agenovir Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Celgene Corporation Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
QB3 Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Agenovir’s complete investors history, request access »